ReviewBest practice & research. Clinical gastroenterology2011
Mechanisms of hepatic fibrogenesis.
Review in Best practice & research. Clinical gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 458 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
458 citing papers in PubMed, 902 citations in OpenAlex.
- Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study.International journal of medical sciences · 2021Trial
- Role of extracellular matrix in liver fibrosis regression and regeneration (Review).International journal of molecular medicine · 2026Review
- Effect of liver fibrosis on gadolinium retention from gadodiamide, gadobutrol, and gadoxetate disodium in rats.Japanese journal of radiology · 2026Article
- The post-transcriptional regulatory RNA-binding protein PTBP1 functions as an inhibitor in hepatic stellate cell activation and liver fibrosis.Molecular medicine (Cambridge, Mass.) · 2026Article
- Plasma cell-free transcriptome profiling in blood plasma from chronic liver disease patients.Scientific data · 2026Article
- Fibrotic microRNAs in the suppression of HSC activation and ECM deposition to facilitate the regression of hepatic fibrosis in zebrafish.Journal of molecular medicine (Berlin, Germany) · 2026Article
- CD36-PPARγ-SPP1 axis mediates hepatocyte-macrophage coordination to drive MASLD-related liver fibrosis.JHEP reports : innovation in hepatology · 2026Article
- Therapeutic Potential of Alginate-Pectin-Chitosan Encapsulated Pediococcus acidilactici Against Bile Duct Ligation-Induced Hepatic Fibrosis in Rats.Probiotics and antimicrobial proteins · 2026Article
- Human FGF1Cells · 2026Article
- Preclinical approaches to studying liver and kidney fibrosis: models and methodologies.Frontiers in pharmacology · 2026Review
- Mechanisms of Action and Biomarker Potential of ncRNAs in Hepatocellular Carcinoma and Liver Fibrosis: A Review.Analytical cellular pathology (Amsterdam) · 2026Review
- Periodontitis and MASLD: a narrative review of the direct oral-hepatic pathway.Frontiers in cellular and infection microbiology · 2026Review
- Livogrit Ameliorates Thioacetamide-Induced Liver Fibrosis and Dyslipidemia in Rat Model by Regulating Oxidative Stress and Hepatic Collagen Levels, in a Non-Mutagenic Manner.Journal of experimental pharmacology · 2026Article
- Hepatic stellate cells in liver fibrosis: From biology to pathology.Open veterinary journal · 2025Review
- Bile canaliculi formation in primary hepatocytes requires α1β1 integrin-dependent adherens junction re-organization.Journal of cell science · 2025Article
- Regression of hepatic fibrosis in gamma-irradiated rats by mycophenolate mofetil: potential role of Egr-1.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Ultrasound image-based contrastive fusion non-invasive liver fibrosis staging algorithm.Abdominal radiology (New York) · 2025Article
- Discovery of novel FABP1 inhibitors for the treatment of metabolic dysfunction-associated steatohepatitis and hepatic fibrosis.BMC chemistry · 2025Article
- Present and Future Perspectives in the Treatment of Liver Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Aluminum adjuvant promotes liver inflammation and fibrosis in mice: A novel approach to establish a liver fibrosis animal model.Liver research (Beijing, China) · 2025Article
398 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Multiple etiologies of liver disease lead to liver fibrosis through integrated signaling networks that regulate the deposition of extracellular matrix. This cascade of responses drives the activation of hepatic stellate cells (HSCs) into a myofibroblast-like phenotype that is contractile, proliferative and fibrogenic. Collagen and other extracellular matrix (ECM) components are deposited as the liver generates a wound-healing response to encapsulate injury. Sustained fibrogenesis leads to cirrhosis, characterized by a distortion of the liver parenchyma and vascular architecture. Uncovering the intricate mechanisms that underlie liver fibrogenesis forms the basis for efforts to develop targeted therapies to reverse the fibrotic response and improve the outcomes of patients with chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.